Skip to main content
. 2014 Jan 27;9(1):e86097. doi: 10.1371/journal.pone.0086097

Table 2. Outcomes of the meta-analysis.

Parameters No. Studies Sample Size Heterogeneity OR 95% CI of Overall Effect P
CIMP+ CIMP−
H. pylori 5 137 243 P = 0.05, I2 = 58% 2.23 1.25–4.00 P = 0.007
EBV 2 40 104 P = 0.39, I2 = 0% 51.27 9.39–279.86 P<0.00001
MSI 4 136 306 P = 0.01, I2 = 71% 4.44 1.17–16.88 P = 0.03
Age 4 87 195 P = 0.52, I2 = 0% 1.10 0.63–1.93 P = 0.74
Gender 9 184 565 P = 0.91, I2 = 0% 0.69 0.48–1.00 P = 0.05
Tumor site 4 85 206 P = 0.17, I2 = 40% 0.85 0.51–1.44 P = 0.55
Pathological type 7 142 440 P = 0.03, I2 = 56% 0.63 0.31–1.28 P = 0.20
Cell differentiation 3 45 264 P = 0.68, I2 = 0% 0.64 0.29–1.42 P = 0.27
TNM stage 4 47 212 P = 0.08, I2 = 56% 1.39 0.54–3.57 P = 0.49
Distant metastasis 4 103 258 P = 0.004, I2 = 77% 1.69 0.37–7.67 P = 0.49
Lymph node metastasis 6 128 349 P = 0.16, I2 = 37% 0.81 0.50–1.31 P = 0.39
5-year survival 2 32 114 P = 0.02, I2 = 82% 0.65 0.04–10.70 P = 0.76

CIMP, CpG island methylator phenotype; CI, confidence interval; EBV, Epstein-Barr virus; H. pylori, Helicobacter pylori; MSI, microsatellite instability; OR, odds ratio.